Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The pharmacogenetics of treatment with olanzapine
Pablo Zubiaur, Paula Soria‐Chacartegui, Gonzalo Villapalos‐García, et al.
Pharmacogenomics (2021) Vol. 22, Iss. 14, pp. 939-958
Open Access | Times Cited: 20

Showing 20 citing articles:

Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics
X.M. Hart, Gerhard Gründer, Nicolas Ansermot, et al.
The World Journal of Biological Psychiatry (2024) Vol. 25, Iss. 9, pp. 451-536
Closed Access | Times Cited: 6
Pharmacogenetics in the Treatment of Huntington’s Disease: Review and Future Perspectives
Xandra García‐González, Esther Cubo, Lucía Simón-Vicente, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 3, pp. 385-385
Open Access | Times Cited: 14
Case report: Avoiding intolerance to antipsychotics through a personalized treatment approach based on pharmacogenetics
Liam Korošec Hudnik, Tanja Blagus, Sara Redenšek, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 4
Assessing Aflatoxin Exposure in the United Arab Emirates (UAE): Biomonitoring AFM1 levels in Urine Samples and their Association with Dietary Habits
Shahd Elabed, Raghad Khaled, Nèjia Farhat, et al.
Environmental Toxicology and Pharmacology (2025), pp. 104644-104644
Open Access
Investigating DRD2 and HTR2A polymorphisms in treatment-resistant schizophrenia: a comparative analysis with other treatment-resistant mental disorders and the healthy state
Antonio Del Casale, Giovanna Gentile, Simone Lardani, et al.
European Archives of Psychiatry and Clinical Neuroscience (2025)
Open Access
In-silico analysis of CYP1A2 (cytochrome P450 1A2) missense mutations: Implications for pharmacogenetics
Yasamin Khiabani, Nazanin Gholampour‐Faroji, Habib Rezanejad, et al.
Heliyon (2025), pp. e42955-e42955
Open Access
Preparation and Optimization of Olanzapine as Transdermal Nanoparticles Delivery System
Abulfadhel Jaber Neamah Al-Shaibani, Mowafaq M. Ghareeb
Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) (2024) Vol. 6, Iss. 2, pp. 76-81
Closed Access | Times Cited: 3
Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review
Bradley Roberts, Zahra Cooper, Stephanie Lu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Human Data on Pharmacokinetic Interactions of Cannabinoids: A Narrative Review
Cecilia Maldonado, Raquel Peyraube, Pietro Fagiolino, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 4, pp. 241-254
Closed Access | Times Cited: 2
Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions
Priyanka Kolli, Grace Kelley, Marianela Rosales, et al.
Pharmacogenomics and Personalized Medicine (2023) Vol. Volume 16, pp. 1097-1108
Open Access | Times Cited: 5
DRD2, DRD3, and HTR2A Single-Nucleotide Polymorphisms Involvement in High Treatment Resistance to Atypical Antipsychotic Drugs
Antonio Del Casale, Maurizio Simmaco, Martina Nicole Modesti, et al.
Biomedicines (2023) Vol. 11, Iss. 7, pp. 2088-2088
Open Access | Times Cited: 4
Formulation, in vitro and in vivo evaluation of olanzapine nanoparticles dissolving microneedles for transdermal delivery
Abulfadhel Jaber Neamah Al-Shaibani, Mowafaq M. Ghareeb
Pharmacia (2024) Vol. 71, pp. 1-13
Open Access | Times Cited: 1
Construction of HumanizedCYP1A2Rats Using CRISPR/CRISPR-Associated Protein 9 to Promote Drug Metabolism and Pharmacokinetic Research
Jie Liu, Jian Lu, Bingyi Yao, et al.
Drug Metabolism and Disposition (2023) Vol. 52, Iss. 1, pp. 56-62
Closed Access | Times Cited: 3
Metabolic, genetic, and pharmacokinetic parameters for the prediction of olanzapine efficacy
Ling Cong, Zirui Wan, Pengfei Li, et al.
European Journal of Pharmaceutical Sciences (2022) Vol. 177, pp. 106277-106277
Open Access | Times Cited: 3
Role of D2 receptor (–141 C Ins/Del) genetic polymorphism on olanzapine-induced adverse drug reaction in schizophrenic patients
Zahra Jawd Mohammed Ali, Atheer Majid Rashid Al-juhiashi
Pharmacia (2024) Vol. 71, pp. 1-8
Open Access
Challenging pharmacotherapy management of a psychotic disorder due to a delicate pharmacogenetic profile and drug-drug interactions: a case report and literature review
Andrej Belančić, Aristea Pavešić Radonja, Lana Ganoci, et al.
Croatian Medical Journal (2024) Vol. 65, Iss. 4, pp. 383-395
Open Access
Correlation of the DRD2 gene polymorphism with psychopathology and predictive antimanic responses in patients with bipolar mania
Hejian Tao, Haiying Jin, Min Xu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Monitoring of the Antipsychotic Therapy Effectiveness
И. И. Мирошниченко
Psikhiatriya (2023) Vol. 20, Iss. 4, pp. 128-138
Open Access | Times Cited: 1
The relationship of cytochrome P450 isoforms with the efficacy and safety of antipsychotic and antidepressant therapy
Sakeena Bairamova, Olga Pavlova, С. В. Шпорт, et al.
S S Korsakov Journal of Neurology and Psychiatry (2023) Vol. 123, Iss. 11, pp. 40-40
Closed Access
Association Studies in Clinical Pharmacogenetics
Pablo Zubiaur, Francisco Abad‐Santos
Pharmaceutics (2022) Vol. 15, Iss. 1, pp. 113-113
Open Access
Page 1

Scroll to top